Bayer Cements Supplement Sales Gains From Initial COVID Boost
A year on from the start of the COVID-19 outbreak and a global rush for supplements, Bayer has cemented these sales gains with slight growth at its Nutritionals business in Q1.
You may also be interested in...
CDER approves Bayer Healthcare’s azelastine 0.15% nasal antihistamine indicated for seasonal and perennial allergic rhinitis in adults and children 6 and older. Bayer says Astepro Allergy is first steroid-free antihistamine for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief.
Bayer Consumer Health is stepping up investments in India, China and South East Asia to unleash untapped potential in these high growth OTC markets.
Enjoying a 5% sales rise, Bayer Consumer Health grew faster than the global market last year, with the company keen to repeat the performance in 2021.